VENUS REMEDIES
|
VENUS REMEDIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 19.87 | 30.47 | 50.04 | -8.10 | -23.15 |
| CEPS(Rs) | 44.04 | 55.55 | 78.63 | 17.84 | 4.38 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 344.38 | 329.50 | 313.18 | 262.01 | 269.42 |
| Tax Rate(%) | 29.96 | -11.85 | -27.21 | -24.44 | 3.87 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.84 | 10.35 | 9.81 | 12.03 | 10.10 |
| EBIT Margin(%) | 6.88 | 6.15 | 11.23 | 1.56 | -1.34 |
| Pre Tax Margin(%) | 6.83 | 6.07 | 8.86 | -2.37 | -9.23 |
| PAT Margin (%) | 4.78 | 6.79 | 11.27 | -2.95 | -8.88 |
| Cash Profit Margin (%) | 10.60 | 12.37 | 17.70 | 6.49 | 1.68 |
| Performance Ratios | |||||
| ROA(%) | 4.50 | 7.18 | 10.30 | -1.45 | -3.85 |
| ROE(%) | 5.90 | 9.85 | 17.40 | -3.05 | -8.23 |
| ROCE(%) | 7.75 | 7.89 | 12.37 | 0.90 | -0.67 |
| Asset Turnover(x) | 0.94 | 1.06 | 0.91 | 0.49 | 0.43 |
| Sales/Fixed Asset(x) | 0.91 | 0.98 | 0.88 | 0.51 | 0.46 |
| Working Capital/Sales(x) | 2.31 | 3.24 | 4.01 | 4.89 | 177.75 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.09 | 1.02 | 1.13 | 1.96 | 2.19 |
| Receivable days | 37.87 | 21.48 | 20.89 | 36.97 | 48.37 |
| Inventory Days | 80.68 | 74.69 | 86.94 | 152.66 | 159.26 |
| Payable days | 55.69 | 57.31 | 57.86 | 76.11 | 65.53 |
| Valuation Parameters | |||||
| PER(x) | 8.15 | 8.82 | 5.49 | - | - |
| PCE(x) | 3.68 | 4.84 | 3.49 | 1.26 | 7.57 |
| Price/Book(x) | 0.47 | 0.82 | 0.88 | 0.09 | 0.12 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.37 | 0.59 | 0.65 | 0.73 | 1.04 |
| EV/Core EBITDA(x) | 2.91 | 5.00 | 4.89 | 5.34 | 8.70 |
| EV/EBIT(x) | 5.36 | 9.54 | 5.83 | 46.42 | -77.79 |
| EV/CE(x) | 0.34 | 0.61 | 0.65 | 0.38 | 0.46 |
| M Cap / Sales | 0.39 | 0.60 | 0.62 | 0.08 | 0.13 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -7.44 | 9.50 | 61.53 | 5.42 | -13.57 |
| Core EBITDA Growth(%) | 0.14 | -4.07 | 59.14 | 19.44 | -7.75 |
| EBIT Growth(%) | 3.62 | -40.09 | 1,061.31 | 222.71 | -153.82 |
| PAT Growth(%) | -34.77 | -34.07 | 717.70 | 65.01 | 6.90 |
| EPS Growth(%) | -34.77 | -39.12 | 717.70 | 65.01 | 6.90 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.09 | 0.10 | 0.13 | 0.68 | 0.90 |
| Current Ratio(x) | 3.91 | 3.00 | 2.40 | 1.31 | 1.01 |
| Quick Ratio(x) | 2.46 | 1.64 | 1.17 | 0.68 | 0.47 |
| Interest Cover(x) | 129.84 | 76.69 | 4.73 | 0.40 | -0.17 |
| Total Debt/Mcap(x) | 0.20 | 0.12 | 0.15 | 7.94 | 7.28 |
Compare Financial Ratios of peers of VENUS REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VENUS REMEDIES | ₹396.1 Cr | -4.6% | -13.8% | 49.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹366,103.0 Cr | 0.7% | -4.8% | 57.3% | Stock Analytics | |
| CIPLA | ₹114,230.0 Cr | 1.9% | -2.4% | 42.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹103,916.0 Cr | 0.1% | 3% | 12.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹99,939.2 Cr | 1.3% | 0.5% | 87.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,732.2 Cr | -5.4% | -4.1% | 20% | Stock Analytics | |
VENUS REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VENUS REMEDIES | -4.6% |
-13.8% |
49.4% |
| SENSEX | -1.5% |
-2.6% |
17.8% |
You may also like the below Video Courses
